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t.2013.08Abstract Objectives: In support with ﬁeld cancerization theory, some patients with lung cancer
(LC) will also have synchronous invasive or pre-invasive bronchial lesions. In this cross sectional
– analytic study autoﬂuorescence bronchoscopy (AFB) was used to assess the prevalence of syn-
chronous lesions in patients with LC.
Materials and methods: All patients with abnormal sputum cytology underwent white light and
AFB. From 335 patients with abnormal sputum cytology referred for AFB, lung cancer was
detected in 91 patients (89 male and 2 female) of age (mean ± SD), 67 ± 8 years. 77 had squamous
cell carcinoma (SqCC), 13 had adenocarcinoma and one patient with small cell lung cancer (SCLC).
Results: Synchronous lesions detected in 26 (29%) patients, 25 (33%) of patients with SqCC, one
with adenocarcinoma, no synchronous lesion detected in one patient with SCLC. The most severe
detected synchronous lesion was adenocarcinoma in one patient, Carcinoma insitu (CIS) in 4
patients, severe dysplasia in 3 patients, moderate dysplasia in 10 patients, and mild dysplasia in 8
patients. Synchronous lesions were more frequently detected in current smokers (35%), than in
ex-smokers (20%) and non-smokers (15%).
Conclusion: Synchronous preinvasive lesions are frequent in patients with LC and AFB should
be included in pre-operative evaluation of these patients.
ª The Egyptian Society of Chest Diseases and Tuberculosis. Open access under CC BY-NC-ND license.(M.A.R. Mahmoud).
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OpIntroduction
The incidence of synchronous primary lung tumors is reported
around 0.2–20% [1] and has been increasing recently due to the
widespread use of imaging modalities such as multislice spiral
computed tomography (CT), ﬂuorescence endoscopy and pos-
itron emission tomography (PET) scanning. The simultaneous
detection of more than one pulmonary nodule in patients with
a lung cancer raises the clinical dilemma of whether these
lesions represent intrapulmonary metastases that migrateden access under CC BY-NC-ND license.
Table 1 Demographic data and primary diagnosis.









Squamous cell carcinoma 77 (85%)
Adenocarcinoma 13 (14%)
Small cell carcinoma 1 (1%)
Table 2 Detected synchronous preinvasive lesions.
Detected synchronous lesions Number of patients Percent
No synchronous lesion 66 72
Mild dysplasia 7 8
Moderate dysplasia 10 11
Severe dysplasia 3 3
Carcinoma insitu 4 5
Adenocarcinoma 1 1
Total 91 100
714 M.A.R. Mahmoud, A. Abdel-azimfrom the same origin or the secondary primary lung tumors.
The criteria proposed by Martini and Melamed [2] in 1975
for the diagnosis of synchronous multiple primary lung tumors
are still commonly used and are primarily based on the histo-
logical characteristics of the tumors, location, presence or
absence of carcinoma in situ, vascular invasion, metastasis
and other empirical features without the biological and molec-
ular bases [3].
Up to 10% of patients successfully treated for primary
NSCLC will develop a second primary lung cancer [1]. Since
diagnosis of a synchronous primary tumor may affect the diag-
nostic work-up and deﬁnite therapy, precise diagnostic proce-
dures are mandatory. Lung imaging ﬂuorescence endoscopy
(LIFE) has proven better than conventional white light bron-
choscopy (WLB) for visualizing premalignant lesions or early
stages of lung cancer [4–6]. However, Kurie et al [7] have cast
a serious doubt on the sensitivity of LIFE and state that LIFE
cannot replace conventional bronchoscopy, but should be used
in addition to WLB. In this study, the prevalence of preinvasive
bronchial lesions in patientswith lung cancerwas estimated, and
its impact on deﬁnite outcome of the patients was evaluated.
Patients and methods
Patients
This cross sectional – analytic study was conducted as part of
Japan lung cancer (LC) early detection program, in which pa-
tients at high risk for LC underwent screening by sputum
cytology; persons with abnormal sputum cytology were sub-
jected to autoﬂuorescence bronchoscopy.
From 335 consecutive patients at risk of LC with abnormal
sputum cytology and underwent AFB examinations at Chiba
University Hospital, Chiba, Japan during the period from
December 1999 to December 2008, 91 patients (89 men and
2 women) were included in the current study. Patients eligible
for this study had LC (non small cell lung cancer or small cell
lung cancer).
Patients’ median age was 68 (mean ± SD, 67 ± 8 years). A
patient was considered an ex-smoker if he/she had stopped
smoking for more than 1 year. All patients underwent white
light (WLB) and autoﬂuorescence bronchoscopy (AFB).
Bronchial biopsy specimens were reviewed by 2 patholo-
gists according to the WHO 1999 criteria for pre-invasive
bronchial lesions [8]. Biopsies were classiﬁed as follows: nor-
mal or inﬂammatory, basal cell hyperplasia (BCH), squamous
metaplasia (SM), mild dysplasia, moderate dysplasia, severe
dysplasia, CIS or squamous cell carcinoma [8].
Endoscopy
WLB was done using a ﬂexible video bronchoscope (BF-240,
Olympus Optical Corporation, Tokyo, Japan until January
2004, and by BF 6C260, Olympus Optical Corporation, To-
kyo, Japan thereafter). WLB was ﬁrst performed under local
anesthesia with sedation by intravenous midazolam and oxy-
gen inhalation. This was followed by AFB using Laser Induced
ﬂuorescent endoscopy (LIFE) (Xillix LIFE; Xillix Technolo-
gies Corp., Richmond, BC, Canada) which was applied using
a ﬁberoptic bronchoscope (BF40; Olympus) from December
1999 to October 2001, or by autoﬂuorescence imaging (AFI)
bronchovideoscope (BF type F260, Olympus Optical Corpora-tion, Tokyo, Japan) thereafter. Biopsy was taken from all sites
that appeared abnormal at white light and/or autoﬂuorescence
bronchoscopy. Biopsies were immediately formalin ﬁxed and
parafﬁn embedded. All participants provided written informed
consent before enrollment into the study. The study was ap-
proved by the Chiba University ethics committee.
Statistical analysis
Statistical analysis was performed using Statistical Package for
the Social Sciences (SPSS software version 12) (SPSS Inc., Chi-
cago, IL). Comparisons were made by Chi-square tests and
bilateral Fisher test, with Yates correction when required.
P< 0.05 was considered statistically signiﬁcant.
Results
The current study included 91 patients, 89 male and 2 females,
smoking status is shown in Table 1 and 77 patients had squa-
mous cell lung cancer (SQCC), 13 had adenocarcinoma while
one patient had small cell lung cancer (SCLL) (Table 1).
Synchronous lesions were detected in 25 patients (28%), 7
patients had mild dysplasia as the most severe synchronous le-
sions, 10 patients had moderate dysplasia, 3 patients had se-
vere dysplasia, 4 patients had carcinoma in situ and one
patient had adenocarcinoma as the most severe detected
Table 1: demographic data and primary diagnosis synchro-
nous lesion (Table 2).
Number of patients with synchronous lesions according to
their primary lung cancer diagnosis is shown in Table 3 and the
distribution of detected synchronous lesions for each lung can-
cer type is shown in Table 4.
Table 3 Detected synchronous lesions according to primary lung cancer.
Primary lung cancer No. of patients with synchronous lesions (%)
Squamous cell carcinoma (77) 25 (33%)
Adenocarcinoma (13) 1 (8%)
Small cell lung cancer (1) 0
Table 5 Detection of synchronous lesions according to smoking status.
Presence of Synchronous lesions
No Yes
Smoking status Non-smoker (6) 5 (83%) 1 (17%)
Ex-smoker (34) 28 (82%) 6 (18%)
Current smoker (51) 32 (71%) 19 (29%)













Squamous (76) 52 (69%) 6 (8%) 10 (13%) 3 (4%) 4 (5%) 1 (1%)
Adenocarcinoma (13) 12 (92%) 1(8%) 0 0 0 0
Small cell carcinoma (1) 1(100%) 0 0 0 0 0
Total 65 7 10 3 4 1
Synchronous invasive or preinvasive bronchial lesions detected by autoﬂuorescence 715Synchronous lesions were more frequently detected in cur-
rent smokers compared to ex-smokers and non-smokers and
this was signiﬁcant (P< 0.05) as shown in Table 5.
Discussion
In the current study we found that the presence of synchronous
invasive or preinvasive bronchial lesions is a frequent ﬁnding
in patients with lung cancer and this was more signiﬁcant
among current smokers compared to non-smokers and ex-
smokers.
More than 50 years ago, Slaughter et al. [9] noted that
smokers developed multiple preneoplastic lesions and synchro-
nous (i.e., those detected simultaneously) or metachronous
(i.e., those detected within a relatively short period) tumors
in the squamous epithelium of the oral cavity, a phenomenon
they termed ‘‘ﬁeld cancerization.’’ They attributed these ﬁnd-
ings to tobacco carcinogens damaging the entire ﬁeld at risk
– the oral mucosa. Several years later, Strong et al. [10] ex-
tended this concept (and the clinical implications) to the entire
upper aerodigestive tract. Multifocal primary tumors having a
similar histological appearance have been described in many
organs but are especially common in lung cancer. Wang
et al. [11] investigated the mechanisms by which these tumors
arise. The results of these studies pose both important biolog-
ical and clinical management questions. Smokers cured of one
aerodigestive cancer, including lung cancer, are at greatly in-
creased risk of developing a second primary malignancy [12].
This event may occur several years later, may involve tumors
of differing histological types, or the tumors may arise in dif-ferent anatomical regions of the ﬁeld (such as the larynx and
lung). The origin of these tumors has been attributed to a
‘‘ﬁeld’’ effect. More controversial are multifocal tumors of sim-
ilar histology that arise synchronously or metachronously in
the same organ. Multifocal tumors may be localized to multi-
ple (satellite) nodules within a small region of the lung, involve
a single lobe or multiple lobes within a single lung, or be pres-
ent in both lungs. Two major mechanisms have been proposed
by which histologically similar multifocal tumors arise: (1) a
single clonal event resulting in a tumor that subsequently
spreads within one or both lungs and (2) multiple tumors are
arising independently in a carcinogen damaged ﬁeld.
Nearly 30 years ago, Martini and Melamed [2] suggested
clinicopathological criteria to help identify the origin of multi-
focal tumors. However, their criteria are guidelines for making
clinical decisions, not deﬁnitive proof of origin. Martini and
Melamed wished to provide guidance for lung cancer surgery;
if the two lesions were thought to be separate lung cancers,
they should be treated ‘‘independently’’ (and resected as such).
By contrast, if they were thought to represent metastases, this
could be taken as an indication of an unresectable disease.
Laboratory investigations to distinguish between these possi-
bilities have resulted in multiple publications for more than
20 years. Many of these publications do not speciﬁcally ad-
dress the question at hand, the sheer number of reports indi-
cate substantial interest in the subject. Wang et al. [11] have
studied two or more synchronous or metachronous tumors
(n= 70) found in 30 patients undergoing resection(s) for lung
cancer at multiple centers. However, the investigators do not
tell us the frequency of multifocal tumors in their series. In ear-
716 M.A.R. Mahmoud, A. Abdel-azimlier relatively small studies, frequencies ranging from 0.2% to
2% were reported, as referenced by Wang et al [11].
However, several more recent larger studies have found fre-
quencies of 3.7–8.0% [13–17]. It is not known whether these
ﬁndings reﬂect a rising incidence, as has been suggested [18],
or simply better imaging procedures, especially the widespread
use of computed tomography (CT) for screening and diagno-
sis. CT is especially efﬁcient for the detection of small periph-
erally arising adenocarcinomas and their putative precursor
lesions, atypical adenomatous hyperplasias.
In Flieder et al. [19] study, multifocal adenocarcinomas
were identiﬁed in 15 of 77 (approximately 20%) resections
for CT screening – identiﬁed lung cancers. Thus, this clinical
problem is likely to become a common event with the wide-
spread application of CT-based screening programs. In addi-
tion Van Rens [20] studied the additional value of using
autoﬂuorescence bronchoscopy for the evaluation of patients
with lung cancer, the study included, sixty-nine patients with
NSCLC and three patients had small cell lung carcinoma.
Apart from the primary lesion, one up to six additional endo-
bronchial lesions were visualized in 48 patients by WLB and/or
LIFE. High-grade dysplastic lesions were detected in ten pa-
tients, three of whom were eligible for surgery of the primary
tumor after completion of the investigations. Three other pa-
tients (4.3%) had synchronous cancers (NSCLC). In one pa-
tient, the lesion was visualized by LIFE and by WLB. The
other two malignant lesions were detected only by LIFE. In
these three latter patients, diagnostic work-up and deﬁnite
treatment was changed, as a result of detection of synchronous
lesions. In concordance with these data, in the current study by
use of autoﬂuorescence bronchoscopy for the evaluation of pa-
tients with lung cancer we found that synchronous invasive or
preinvasive bronchial lesions are a frequent ﬁnding in patients
with lung cancer and it is more frequent in current smokers.
Conclusions
Synchronous preinvasive lesions are frequent in patients with
LC and AFB should be included in pre-operative evaluation
of these patients. The use of AFB for preoperative evaluation
of patients with lung cancer is recommended.
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